NcXHF

SQUAMOUS, SMALL CELL, AND RARE LUNG CANCERS
tumor activities alone/in combination with gemcitabine. Invest New
Drugs. 2014;32:825-837.
30. Fry DW, Harvey PJ, Keller PR, et al. Specifıc inhibition of cyclindependent
kinase 4/6 by PD 0332991 and associated antitumor activity
in human tumor xenografts. Mol Cancer Ther. 2004;3:1427-1438.
31. George S, Kasimis BS, Cogswell J, et al. Phase I study of flavopiridol in
combination with Paclitaxel and Carboplatin in patients with nonsmall-cell
lung cancer. Clin Lung Cancer. 2008;9:160-165.
32. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer.
Oncology. 2005;69:4-10.
33. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase
II trial comparing bevacizumab plus carboplatin and paclitaxel with
carboplatin and paclitaxel alone in previously untreated locally advanced
or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22:
2184-2191.
34. Hainsworth JD, Fang L, Huang JE, et al. BRIDGE: an open-label phase
II trial evaluating the safety of bevacizumab carboplatin/paclitaxel
as fırst-line treatment for patients with advanced, previously untreated,
squamous non-small cell lung cancer. J Thorac Oncol. 2011;6:
109-114.
35. Hellmann MD, Chaft JE, Rusch V, et al. Risk of hemoptysis in patients
with resected squamous cell and other high-risk lung cancers treated
with adjuvant bevacizumab. Cancer Chemother Pharmacol. 2013;72:
453-461.
36. Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel
versus placebo plus docetaxel for second-line treatment of stage IV
non-small-cell lung cancer after disease progression on platinumbased
therapy (REVEL): a multicentre, double-blind, randomised
phase 3 trial. Lancet. 2014;384:665-673.
37. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation
with clinical response to gefıtinib therapy. Science. 2004;304:
1497-1500.
38. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are
common in lung cancers from “never smokers” and are associated with
sensitivity of tumors to gefıtinib and erlotinib. Proc Natl Acad Sci U S
A. 2004;101:13306-13311.
39. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor
gene and protein and gefıtinib sensitivity in non-small-cell lung
cancer. J Natl Cancer Inst. 2005;97:643-655.
40. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy
in patients with advanced non-small-cell lung cancer (FLEX): an openlabel
randomised phase III trial. Lancet. 2009;373:1525-1531.
41. Pirker R, Pereira JR, von Pawel J, et al. EGFR expression as a predictor
of survival for fırst-line chemotherapy plus cetuximab in patients with
advanced non-small-cell lung cancer: analysis of data from the phase 3
FLEX study. Lancet Oncol. 2012;13:33-42.
42. Thatcher N, Hirsch F, Szczesna A, et al. A randomized, multicenter,
open-label, phase III study of gemcitabine-cisplatin (GC) chemotherapy
plus necitumumab (IMC-11F8/LY3012211) versus GC
alone in the fırst-line treatment of patients (pts) with stage IV squamous
non-small cell lung cancer (sq-NSCLC). J Clin Oncol. 2014;
32:5s (suppl; abstr 8008).
43. Postow MA, Callahan MK, Wolchok JD. Immune Checkpoint Blockade
in Cancer Therapy. J Clin Oncol. Epub 2015 Jan 20.
44. Rizvi N, Garon E, Patnaik A, et al. Safety and clinical activity of MK-
3475 as initial therapy in patients with advanced non-small cell lung
cancer (NSCLC). J Clin Oncol. 2014;32:5s (suppl; abstr 8007).
45. Gettinger S, Shepherd F, Antonia S, et al. First-line nivolumab (anti-
PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC:
safety, effıcacy, and correlation of outcomes with PD-L1 status. J Clin
Oncol. 2014;32:5s (suppl; abstr 8024).
46. Brahmer J, Rizvi N, Lutzky J, et al. Clinical activity and biomarkers of
MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC. J Clin
Oncol. 2014;32:5s (suppl; abstr 8021).
47. National Lung Screening Trial Research Team, Aberle DR, Adams
AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic
screening. N Engl J Med. 2011;365:395-409.
48. Babakoohi S, Fu P, Yang M, et al. Combined SCLC clinical and pathologic
characteristics. Clin Lung Cancer. 2013;14:113-119.
49. Turrisi AT 3rd, Kim K, Blum R, et al. Twice-daily compared with oncedaily
thoracic radiotherapy in limited small-cell lung cancer treated
concurrently with cisplatin and etoposide. N Engl J Med. 1999;340:265-
271.
50. Murray N, Coy P, Pater JL, et al. Importance of timing for thoracic
irradiation in the combined modality treatment of limited-stage smallcell
lung cancer. The National Cancer Institute of Canada Clinical Trials
Group. J Clin Oncol. 1993;11:336-344.
51. Jeremic B, Shibamoto Y, Acimovic L, et al. Initial versus delayed accelerated
hyperfractionated radiation therapy and concurrent chemotherapy
in limited small-cell lung cancer: a randomized study. J Clin
Oncol. 1997;15:893-900.
52. Aupérin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation
for patients with small-cell lung cancer in complete remission.
Prophylactic Cranial Irradiation Overview Collaborative Group.
N Engl J Med. 1999;341:476-484.
53. Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation
in extensive small-cell lung cancer. N Engl J Med. 2007;357:
664-672.
54. Seto T, Takahashi T, Yamanaka T, et al. Prophylactic cranial irradiation
(PCI) has a detrimental effect on the overall survival (OS) of patients
(pts) with extensive disease small cell lung cancer (ED-SCLC):
results of a Japanese randomized phase III trial. J Clin Oncol. 2014;
32:5s (suppl; abstr 7503).
55. Slotman BJ, van Tinteren H, Praag JO, et al. Use of thoracic radiotherapy
for extensive stage small-cell lung cancer: a phase 3 randomised
controlled trial. Lancet. 2015;385:36-42.
56. Peifer M, Fernández-Cuesta L, Sos ML, et al. Integrative genome analyses
identify key somatic driver mutations of small-cell lung cancer.
Nat Genet. 2012;44:1104-1110.
57. Rudin CM, Durinck S, Stawiski EW, et al. Comprehensive genomic
analysis identifıes SOX2 as a frequently amplifıed gene in small-cell
lung cancer. Nat Genet. 2012;44:1111-1116.
58. Hodgkinson CL, Morrow CJ, Li Y, et al. Tumorigenicity and genetic
profıling of circulating tumor cells in small-cell lung cancer. Nat Med.
2014;20:897-903.
59. Han JY, Lee YS, Kim BC, et al. Whole-genome analysis of a patient with
early-stage small-cell lung cancer. Pharmacogenomics J. 2014;14:503-
508.
60. Wildey G, Chen Y, Lent I, et al. Pharmacogenomic approach to identify
drug sensitivity in small-cell lung cancer. PLoS One. 2014;9:
e106784.
61. Sos ML, Dietlein F, Peifer M, et al. A framework for identifıcation of
actionable cancer genome dependencies in small cell lung cancer. Proc
Natl Acad SciUSA.2012;109:17034-17039.
62. Christensen CL, Kwiatkowski N, Abraham BJ, et al. Targeting transcriptional
addictions in small cell lung cancer with a covalent CDK7
inhibitor. Cancer Cell. 2014;26:909-922.
63. Dabir S, Babakoohi S, Kluge A, et al. RET mutation and expression in
small-cell lung cancer. J Thorac Oncol. 2014;9:1316-1323.
64. Umemura S, Mimaki S, Makinoshima H, et al. Therapeutic priority of
the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed
by a comprehensive genomic analysis. J Thorac Oncol. 2014;9:1324-
1331.
65. Owonikoko TK, Zhang G, Deng X, et al. Poly (ADP) ribose polymerase
asco.org/edbook | 2015 ASCO EDUCATIONAL BOOK 159